Challenges in Measuring Clinical Effectiveness in COPD and Potential Use of Real-World Evidence to Reduce Uncertainty

IMI Get Real work package 1 Case Study


Our analysis focused on mentioned uncertainties in the clinical evidence that emerged from regulatory and reimbursement assessments for COPD drugs approved by the EMA, Health Canada (HC), and/or the Therapeutic Goods Administration (TGA) between 2010 – 2015. We categorized the agencies' questioning of uncertainty around validity and applicability of efficacy data to help inform a decision-making framework for including RWE earlier in drug development to reduce such uncertainties.

Read full analysis and conclusions in the research brief.

Original research presented at ISPOR 2016 in Washington, DC.

Register to Download Research Brief

Name *
Communication Preferences
Thank you for your interest in Context Matters. You will receive future communications. To opt-out, check the box below.